ANDA 211001, held by Meitheal Pharmaceuticals. Bendamustine Hydrochloride.
As of Nov 21, 2026, ANDA 211001 (Bendamustine Hydrochloride), held by Meitheal Pharmaceuticals, was first approved by FDA on Jun 5, 2023, with 0 approved supplements and 0 published complete response letters.
Bendamustine Hydrochloride for Injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. 1.1 Chronic Lymphocytic Leukemia (CLL) Bendamustine Hydrochloride for Injection is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2023 | Original application | Approved |
| Bendamustine Hydrochloride25MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Rx |
| Bendamustine Hydrochloride100MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters